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Abstract: Objective: To evaluate the association of serum malondialdehyde low-density lipoprotein
(MDA-LDL), an oxidatively modified LDL, with the prevalence of high-risk plaques (HRP) deter-
mined with coronary computed tomography angiography (CTA) in statin-treated patients. Methods:
This study was a single-center retrospective cohort comprising 268 patients (mean age 67 years,
58% men) with statin therapy and who underwent coronary CTA for suspected stable coronary
artery disease. Patients were classified into two groups according to median MDA-LDL level or
median LDL-C level. Coronary CTA-verified HRP was defined when two or more characteristics,
including positive remodeling, low-density plaques, and spotty calcification, were present. Results:
Patients with HRP had higher MDA-LDL (p = 0.011), but not LDL-C (p = 0.867) than those without
HRP. High MDA-LDL was independently associated with HRP (odds ratio 1.883, 95% confidential
interval 1.082–3.279) after adjustment for traditional risk factors. Regarding incremental value of
MDA-LDL for predicting CTA-verified HRP, addition of serum MDA-LDL levels to the baseline
model significantly increased global chi-square score from 26.1 to 32.8 (p = 0.010). Conclusions: A
high serum MDA-LDL level is an independent predictor of CTA-verified HRP, which can lead to
cardiovascular events in statin-treated patients.
Keywords: malondialdehyde low-density lipoprotein; high-risk plaque; coronary computed tomog-
raphy angiography; statin
1. Introduction
Cardiovascular disease is the leading global cause of adult mortality and morbid-
ity [1]. Many studies have demonstrated a beneficial effect of low-density lipoprotein
(LDL)-lowering therapies by statins on cardiovascular outcomes [2,3]. Lowering low-
density lipoprotein cholesterol (LDL-C) is the primary target in cardiovascular disease
prevention; however, despite effective LDL-lowering treatment, substantial patients remain
at cardiovascular risk [4]. Among several lipid markers, serum malondialdehyde low-
density lipoprotein (MDA-LDL), which is an oxidatively modified LDL, has been reported
to be associated with coronary plaque vulnerability [5], adverse clinical outcomes after
percutaneous coronary intervention [6], and the incidence of acute coronary syndrome [7].
However, the clinical relevance of serum MDA-LDL levels in patients receiving statin
therapy for cardiovascular events has not been fully elucidated.
Coronary computed tomography angiography (CTA) is used to noninvasively eval-
uate coronary artery disease [8]. In addition to the evaluation of stenosis, coronary CTA
identifies characteristics of plaque composition. Many observational follow-up studies
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have demonstrated the association between high-risk plaques (HRP) by coronary CTA and
cardiovascular events [9,10]. Although statins contribute to the stabilization of plaques [11],
HRP is often detected by coronary CTA even in patients receiving statin therapy.
Therefore, we hypothesized that serum MDA-LDL levels in patients with statin
therapy is involved in the prevalence of HRP by coronary CTA. The aim of this study
was to clarify the association between serum MDA-LDL levels and the prevalence of HRP,
which increases the likelihood of acute coronary events in patients with suspected stable
coronary artery disease receiving statin therapy.
2. Materials and Methods
2.1. Study Population and Risk Assessment
This single-center retrospective study included 268 outpatients who underwent coro-
nary CTA from August 2011 to December 2018 at Okayama University Hospital. A flow
diagram of this study is shown in Figure 1. Participants had no history of coronary artery
disease but had been taking statins.
Figure 1. Study flowchart. CTA, computed tomography angiography; CVD, cardiovascular disease;
MDA-LDL, malondialdehyde-modified low-density lipoprotein.
Hypertension was defined as systolic blood pressure (BP) ≥140 mmHg or diastolic
BP ≥90 mmHg, and/or the use of antihypertensive medication. Diabetes mellitus was
defined as a fasting blood glucose concentration of ≥126 mg/dL or postprandial blood
glucose concentration of ≥200 mg/dL, and/or the use of insulin or oral hypoglycemic
medication. medication. Smoking was defined as a self-reported history of current smoking.
This study was conducted according to the principles of the Declaration of Helsinki and
approved by the ethics committees of Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences. All patients enrolled in the study provided written
informed consent.
2.2. Blood Sampling and the Measurement of MDA-LDL
Blood samples were collected from the antecubital vein after fasting overnight on
the day of coronary CTA. MDA-LDL levels were measured using an enzyme-linked im-
munosorbent assay kit (Sekisui Medical Co., Tokyo, Japan), as described previously [12].
2.3. Acquisition and Analyses of Coronary CTA Image
CT images were acquired using a Somatom Definition Flash scanner (Siemens Medical
Solutions, Munich, Germany) as described previously [13]. Coronary artery plaques
were evaluated on axial and curved multiplanar reformatted images using commercially
available cardiac reconstruction software (Virtual Place, Raijin; AZE Inc., Tokyo, Japan).
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Interpretation of coronary CTA was evaluated by two experienced cardiologists. Significant
coronary artery stenosis was defined as a luminal narrowing of >50%. Coronary plaque
was defined as a structure >1 mm2 located within the vessel wall, and plaque density was
calculated for all lesions [14]. Plaques with a CT attenuation number <50 Hounsfield units
were defined as low-density plaques. Positive remodeling, which indicates an enlarged
vessel to compensate for atherosclerotic change, was assessed visually on multiplanar
reformatted images that were reconstructed in long-axis and short-axis views of the vessel.
Positive remodeling was defined as a threshold of 1.1 for the maximal diameter of the vessel.
Spotty calcification was defined as a calcium burden length <1.5 times the vessel diameter
and a width of less than two-thirds of the vessel diameter. CT-verified high-risk plaques
were defined when two or more plaque characteristics, including positive remodeling,
low-density plaques, and spotty calcification, were present [14].
2.4. Outcome Data
Follow-up clinical information was obtained from a review of the medical records
or telephone interviews by attending physicians. Cardiovascular events were defined as
a composite of cardiac death and acute coronary syndrome. Cardiac death was defined
as death from myocardial infarction, cardiogenic shock, cardiac failure, or ventricular
arrhythmias. Acute coronary syndrome included myocardial infarction and unstable
angina. Non-fatal myocardial infarction was defined using the criteria of typical acute chest
pain and persistent ST-segment elevation or positive cardiac enzymes. Unstable angina
pectoris was defined as typical acute chest pain with negative cardiac enzymes if coronary
artery disease could not be excluded as the cause of symptoms in accordance with current
guidelines [15].
2.5. Statistical Analysis
Continuous variables were expressed as mean ± standard deviation or median with
interquartile range. Dichotomous variables were expressed as numbers and percentages.
Differences in continuous variables between the two groups were analyzed using Student’s
t-test and the Mann–Whitney U-test, as appropriate. Categorical data were compared by χ2
analysis and Fisher’s test, as appropriate. Patients were classified into two groups based on
the median serum MDA-LDL level (93 U/L): high MDA-LDL group (≥93 U/L, n = 139) and
low MDA-LDL group (<93 U/L, n = 129), or LDL-C level (104 mg/dL): high LDL-C group
(≥104 mg/dL, n = 136) and low MDA-LDL group (<104 mg/dL, n = 132). Associations
between serum MDA-LDL and each variable were assessed using Pearson’s correlation
coefficient. Univariate and multivariate logistic regression analyses were performed to
evaluate the association between serum MDA-LDL levels and CTA-verified HRP. A receiver
operating characteristic (ROC) curve was generated to evaluated diagnostic value to predict
the presence of HRP. The increased discriminative value after the addition of serum MDA-
LDL levels to the baseline model in predicting the presence of HRP was assessed by
the global chi-square test and ROC curve analysis. ROC curves were built based on a
logistic regression model, and the Delong test was used to compare the C-statistics. The
net reclassification improvement and integrated discrimination improvement were also
calculated. The baseline model consisted of established clinical risk factors with p < 0.05 by
univariate logistic regression analysis. Cumulative survival estimates were calculated using
the Kaplan–Meier method and compared with the log-rank test. A Cox proportional hazard
model was used to identify whether serum MDA-LDL was associated with cardiovascular
events. All reported p-values were two-sided, and p < 0.05 was considered statistically
significant. Statistical analyses were performed using SPSS statistical software (Version 24;
IBM Corp., Armonk, NY, USA).
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3. Results
3.1. Patient Characteristics
The baseline characteristics of the patients are summarized in Table 1. The mean age was
67 years, and 58% of the patients were men. A share of 76% of patients had hypertension and
46% had diabetes mellitus. Age, sex, prevalence of hypertension, diabetes mellitus, current
smoking status, medications, renal function, hemoglobin A1c, and high-sensitivity CRP did
not differ between the high and low MDA-LDL groups. Patients with high MDA-LDL had
greater body mass index (p = 0.016), and higher levels of LDL-C (p < 0.001) and triglyceride
(p < 0.001), than those with low MDA-LDL. Patients with high MDA-LDL had greater body
mass index (p = 0.016), and higher levels of LDL-C (p < 0.001) and triglyceride (p < 0.001), and
a lower proportion of patients achieved LDL-C <70 mg/dL, than those with low MDA-LDL.
Table 1. Baseline patient demographic and clinical characteristics according to high or low levels of MDA-LDL.
All Patients High MDA-LDL(≥93 U/L)
Low MDA-LDL
(<93 U/L) p-Value
n 268 139 129
Age, year 67 ± 11 67 ± 11 68 ± 11 0.521
Male sex 154 (58) 76 (55) 78 (61) 0.338
Body mass index, kg/m2 24.6 ± 4.1 25.2 ± 3.9 24.0 ± 4.2 0.016
Hypertension 203 (76) 109 (78) 94 (73) 0.290
Diabetes mellitus 122 (46) 59 (42) 63 (49) 0.294
Current Smoker 70 (26) 36 (26) 34 (26) 0.932
Medications
Beta blockers 71 (27) 37 (27) 34 (26) 0.933
CCBs 122 (46) 70 (50) 52 (40) 0.099
ACE-Is or ARBs 135 (50) 73 (53) 62 (48) 0.466
Oral antihyperglycemic drugs 86 (32) 45 (32) 41 (32) 0.918
Ezetimibe 15 (6) 10 (7) 5 (4) 0.293
Statin intensity, low/moderate * 160 (60)/108 (40) 76 (55)/63 (45) 84 (65)/45 (35) 0.082
Statin type, dosage
Atorvastatin, 5 mg/10 mg 18/49 5/26 13/23
Fluvastatin, 20 mg/40 mg 4/1 3/1 1/0
Pitavastatin, 1 mg/2 mg/4 mg 14/28/4 6/13/3 8/15/1
Pravastatin, 5 mg/10 mg 9/36 5/21 4/15
Rosuvastatin, 2.5 mg/5 mg/10 mg 68/24/2 30/19/2 38/5/0
Simvastatin, 5 mg/10 mg 8/3 4/1 4/2
Laboratory findings
Creatinine, mg/dL 0.89 ± 0.78 0.85 ± 0.64 0.93 ± 0.92 0.397
eGFR, mL/min/1.73 m2 68 ± 18 68 ± 17 69 ± 19 0.665
Total cholesterol, mg/dL 186 ± 40 203 ± 40 168 ± 31 <0.001
LDL cholesterol, mg/dL 107 ± 32 122 ± 33 90 ± 22 <0.001
HDL cholesterol, mg/dL 58 ± 17 57 ± 17 60 ± 17 0.080
Triglyceride, mg/dL 121 (88, 171) 150 (104, 198) 101 (76, 130) <0.001
MDA-LDL, U/L 96 ± 35 122 ± 28 69 ± 15 <0.001
HbA1c, % 6.6 ± 1.3 6.6 ± 1.4 6.6 ± 1.3 0.968
hsCRP, mg/dL 0.08 (0.05, 0.18) 0.08 (0.04, 0.16) 0.08 (0.05, 0.20) 0.608
Patients achieving LDLcholesterol
<70 mg/dL 24 (9) 1 (1) 23 (18) <0.001
Data are presented as mean ± standard deviation, number (%), or median (25th, 75th percentile). MDA-LDL, malondialdehyde low-density
lipoprotein cholesterol; CCBs, calcium channel blockers; ACE-Is, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor
blockers; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, glycated
hemoglobin A1c; hsCRP, high-sensitivity C-reactive protein. * No patients received high-intensity statins.
In addition, simple correlation coefficients for the association between serum MDA-
LDL and other lipid variables were analyzed. Serum MDA-LDL levels were significantly
positively associated with total cholesterol (r = 0.52, p < 0.001), LDL-C (r = 0.60, p < 0.001),
and log-transformed triglyceride (r = 0.34, p < 0.001), and were significantly inversely
associated with high-density lipoprotein cholesterol (HDL) (r = −0.14, p = 0.025).
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3.2. MDA-LDL and Coronary CTA Findings
Among all patients, the prevalence of HRP and significant stenosis presented in 87 pa-
tients (32%) and 120 patients (45%), respectively. As shown in Figure 2A, the prevalence of
HRP in the high MDA-LDL group was significantly greater than that in the low MDA-LDL
group (p = 0.040). However, no differences in the prevalence of calcified plaques (p = 0.904),
non-calcified plaques (p = 0.267), low-density plaque (p = 0.344), positive remodeling
(p = 0.057), spotty calcification (p = 0.883), and significant stenosis (p = 0.355) were found
between the high and low MDA-LDL groups. Figure 2B shows no differences in the
prevalence of HRP (p = 0.4111) and significant stenosis (p = 0.229), or other plaque features,
between the high and low LDL-C groups.
Figure 2. The prevalence of coronary plaque characteristics according to MDA-LDL and LDL-C.
(A) Patients were divided into two groups based on the median value of MDA-LDL. (B) Patients
were divided into two groups based on the median value of LDL-C. MDA-LDL, malondialdehyde-
modified low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; CP, calcified plaque;
NCP, non-calcified plaque; LDP, low density plaque; PR, positive remodeling; SC, spotty calcification;
HRP, high-risk plaque: SS, significant stenosis.
As shown in Table 2, patients with HRP had a higher prevalence of male gender
(p < 0.001), hypertension (p = 0.031), and diabetes mellitus (p = 0.028) compared with
patients without HRP. Patients with HRP had lower HDL-C levels (p = 0.014) and serum
MDA-LDL levels (p = 0.011), whereas LDL-C levels did not differ between patients with
and without HRP. Although patients with significant stenosis had higher prevalence of
male gender (p < 0.001) and diabetes mellitus (p = 0.039) compared with patients without
significant stenosis, serum levels of LDL-C and MDA-LDL did not differ between patients
with and without significant stenosis.
As shown in Table 3, in univariate logistic regression analysis, male sex, hypertension,
diabetes mellitus, HDL, and MDA-LDL, but not LDL-C, were significantly associated
with the presence of HRP. In multivariate logistic regression analysis, MDA-LDL was
independently associated with the presence of HRP with an odds ratio of 1.883 (95%
confidence interval 1.082–3.279, p = 0.025). When serum MDA-LDL levels were added to the
baseline model, global chi-square scores significantly increased from 24.0 to 31.6 (p = 0.006).
The net reclassification improvement and integrated discrimination improvement were
significantly improved by 0.282 (p = 0.029) and 0.030 (p = 0.008), respectively. However, the
increase in the C-statistic was not significant (0.68 to 0.70, p = 0.352).
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Table 2. Comparison of patient characteristics according to coronary CTA findings.
Variables
High-Risk Plaque Significant Stenosis
Present Absent p Value Present Absent p Value
n 87 181 119 148
Age, year 68 ± 10 67 ± 12 0.747 68 ± 11 67 ± 12 0.489
Male sex 64 (74) 90 (50) <0.001 84 (70) 70 (47) <0.001
Body mass index, kg/m2 24.7 ± 3.4 24.5 ± 4.4 0.718 24.4 ± 4.1 24.7 ± 4.1 0.450
Hypertension 73 (84) 130 (76) 0.031 93 (78) 110 (74) 0.546
Diabetes mellitus 48 (55) 74 (41) 0.028 63 (53) 59 (40) 0.039
Current smoker 29 (33) 41 (23) 0.062 32 (27) 38 (25) 0.854
Oral antihyperglycemic drugs 32 (37) 54 (30) 0.254 42 (35) 44 (30) 0.333
Creatinine, mg/dL 1.00 ± 0.99 0.83 ± 0.65 0.087 0.91 ± 0.71 0.88 ± 0.83 0.066
Total cholesterol, mg/dL 186 ± 45 187 ± 38 0.834 183 ± 41 188 ± 38 0.300
LDL cholesterol, mg/dL 107 ± 37 107 ± 30 0.867 106 ± 34 107 ± 31 0.728
HDL cholesterol, mg/dL 55 ± 16 60 ± 17 0.014 58 ± 18 58 ± 16 0.905
Triglyceride, mg/dL 130 (90, 182) 117 (85, 170) 0.206 118 (86, 158) 122 (89, 183) 0.155
MDA-LDL, U/L 105 ± 40 92 ± 32 0.011 96 ± 33 96 ± 36 0.979
HbA1c, % 6.7 ± 1.3 6.5 ± 1.4 0.347 6.6 ± 1.3 6.5 ± 1.4 0.122







Table 3. Univariate and multivariate predictors of the presence of HRP.
Univariate Multivariate
Odds Ratio (95%CI) p Value Odds Ratio (95%CI) p Value
Age, per 1 year 1.004 (0.981–1.028) 0.746
Male 2.814 (1.609–4.918) <0.001 2.749 (1.502–1.502) 0.001
Hypertension 2.046 (1.060–3.947) 0.033 2.027 (1.022–4.019) 0.049
Diabetes Mellitus 1.780 (1.062–2.982) 0.029 1.630 (0.941–2.824) 0.081
Current smoker 1.707 (0.970–3.006) 0.064
HDL cholesterol, per 1 mg/dL 0.980 (0.964–0.996) 0.015 0.994 (0.977–1.012) 0.531
LDL cholesterol, >104 mg/dL 0.807 (0.483–1.347) 0.412
Triglyceride *, per 1 index 1.454 (0.854–2.475) 0.168
MDA-LDL, >93 U/L 1.722 (1.024–2.897) 0.041 1.883 (1.082–3.279) 0.025
hsCRP *, per 1 index 0.983 (0.793–1.219) 0.878
HRP, high-risk plaques; LDL, low-density lipoprotein; HDL-C, high-density lipoprotein; MDA-LDL, malondialdehyde low-density
lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein. * Triglyceride and hsCRP were logarithm-transformed.
3.3. Prognostic Impact of HRP and MDA-LDL for Cardiovascular Events
During a median follow-up period of 2.5 years, 11 cardiovascular events (two cardiac
deaths, nine acute coronary syndrome) occurred. Kaplan–Meier curves showed that the
high MDA-LDL group had more cardiovascular events than the low MDA-LDL group
(p = 0.012, log-rank test) (Figure 3A), whereas no significant difference in the incidence
of cardiovascular events was observed between patients with the high and low LDL-
C groups (Figure 3B). Cox univariate regression analysis showed that high MDA-LDL
(HR 5.717, 95%CI 1.225–26.670, p = 0.027), but not high LDL-C (hazard ratio 2.697, 95%
confidence interval 0.715–10.183, p = 0.143), was significantly associated with cardiovascular
events. In age and sex adjusted Cox multivariate regression analysis, high MDA-LDL was
independently associated with cardiovascular events (hazard ratio 5.865, 95% confidence
interval 1.250–27.512, p = 0.025).
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Figure 3. Kaplan–Meier curves of cumulative incidence of cardiovascular events. Kaplan–Meier
curves (A) according to low or high MDA-LDL, and (B) according to low or high LDL-C. MDA-LDL,
malondialdehyde-modified low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol.
4. Discussion
This study demonstrated that serum MDA-LDL, but not LDL-C, was significantly
associated with the presence of HRP and had a moderate incremental value to predict HRP
over traditional risk factors in statin-treated patients with suspected coronary artery disease.
In addition, high MDA-LDL was shown to be a possible predictor for cardiovascular events
defined as a composite of cardiac death and ACS in statin-treated patients.
Although increased oxidized LDL, including serum MDA-LDL, is known to be a
predictor for atherosclerotic cardiovascular diseases [16], the clinical impact of serum
MDA-LDL in patients receiving statin therapy has not been clarified. High triglyceride
levels and low HDL levels have been known as risk markers in patients treated with
lipid-lowering therapy [17]. These lipid abnormalities are associated with an increase in
small dense LDL [18], which are more susceptible to oxidative modification compared with
LDL. Even after considering triglyceride and HDL-C, this study clearly demonstrated that
serum MDA-LDL is a relevant biomarker for the presence of HRP in statin-treated patients.
Oxidized LDL plays a critical role in plaque vulnerability. Oxidized LDL through
lectin-like oxidized LDL receptor-1, which is the major receptor for oxidized LDL in
endothelial cells, contributes to increased matrix metalloproteinase activity [19]. In addition,
elevated concentrations of oxidized LDL induce apoptosis in vascular smooth muscle
cells [20]. Enhanced matrix metalloproteinase production and apoptosis of vascular smooth
muscle cells contribute to plaque instability [21]. Several previous clinical studies reported
that serum MDA-LDL levels have been associated with thin-cap fibroatheroma identified
by frequency-domain optical coherence tomography or with tissue characteristics evaluated
by integrated backscatter intravascular ultrasound, both of which are considered to be
indicators of plaque vulnerability [5,22]. However, these studies only included patients
with obstructive coronary artery disease. In addition, previous studies have reported an
association between serum MDA-LDL and plaque vulnerability in lesions targeted for
revascularization.
Our findings suggest that serum MDA-LDL is an independent factor for cardiovas-
cular events such as cardiac death and acute coronary syndrome. Similar to our results,
a recent clinical study demonstrated that small dense LDL, which is easily oxidized to
MDA-LDL, was strongly associated with myocardial infarction [23]. In fact, oxidized
LDL is also reported to be involved in platelet activation [24]. The significant association
between MDA-LDL and HRP shown in this study may partly explain the role of MDA-LDL
as a predictor of cardiovascular events; nevertheless, further studies are required to clarify
whether there is a causal relationship.
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Statin therapies have been shown to decrease not only LDL but also serum MDA-
LDL [25]. In fact, the current study demonstrated that LDL-C had a significant correlation
with serum MDA-LDL, and the proportion of patients achieving LDL-C < 70 mg/dL
in the low MDA-LDL group was significantly greater than that in the high MDA-LDL
group. In addition, inflammation has been considered as a residual risk in statin-treated
patients, and a previous study reported that oxidized LDL-induced interleukins (IL)-1β
secretion promotes foam cell formation [26]. Recently, a clinical trial showed that antibody
therapy against IL-1β significantly reduced cardiovascular events without lowering lipid
or blood pressure [27]. Further studies are needed to investigate whether additional anti-
inflammatory treatment in patients with high MDA-LDL will reduce cardiovascular events.
Our study has some limitations that need to be addressed. First, this was a single-
center study and the number of patients was relatively small. Patient selection may have
been biased and a prospective study would be preferable. Second, we included only
Japanese patients with suspected stable coronary artery diseasse; the results cannot be
applied to other ethnic groups and the general population. Third, the follow-up study
was relatively short and a small number of cardiovascular events were documented. To
determine the impact of MDA-LDL on cardiovascular death and acute coronary syndrome
in statin-treated patients, a large long-term study is warranted.
5. Conclusions
Our study demonstrated that serum MDA-LDL was significantly associated with
HRP and had an incremental value to predict HRP over traditional risk factors in statin-
treated patients with suspected stable coronary artery disease. Our results suggest the
measurement of serum MDA-LDL is useful in identifying patients likely to have HRP who
are at high risk. Further studies with larger sample size are needed to prove the association
between serum MDA-LDL and cardiovascular events in statin-treated patients.
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